Cerebrolysin is approved in over 50 countries (primarily Europe and Asia) for specific neurological indications including stroke, traumatic brain injury, and dementia, but not for cognitive enhancement in healthy populations
They work by mimicking the GLP-1 hormone produced in the intestine, which stimulates insulin release, reduces glucagon, slows gastric emptying, and promotes feelings of fullness
Clinical studies demonstrate that oral semaglutide produces weight loss results akin to its injectable counterpart
Patients treated with GLP-1 based peptides pre-IVF who lost 5-10% of weight had increased implantation and live birth rates compared to historical controls
Individuals taking Semaglutide typically experience a reduction in body weight ranging from 12-15%, with the most significant decreases usually observed within the initial 12 weeks of administration